PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-7.00%
Negative revenue growth while ADI stands at 13.36%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-6.56%
Negative gross profit growth while ADI is at 12.79%. Joel Greenblatt would examine cost competitiveness or demand decline.
-0.77%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-1.89%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
4.76%
Positive net income growth while ADI is negative. John Neff might see a big relative performance advantage.
3.90%
Positive EPS growth while ADI is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
5.26%
Positive diluted EPS growth while ADI is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-0.82%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.77%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
11.84%
Dividend growth above 1.5x ADI's 0.93%. David Dodd would verify if the firm's cash flow is robust enough for these payouts.
1.49%
OCF growth above 1.5x ADI's 0.42%. David Dodd would confirm a clear edge in underlying cash generation.
-0.31%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
40.82%
10Y revenue/share CAGR under 50% of ADI's 85.11%. Michael Burry would suspect a lasting competitive disadvantage.
4.85%
5Y revenue/share CAGR under 50% of ADI's 22.23%. Michael Burry would suspect a significant competitive gap or product weakness.
17.82%
3Y revenue/share CAGR under 50% of ADI's 37.35%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
149.80%
10Y OCF/share CAGR above 1.5x ADI's 16.29%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
34.74%
Positive OCF/share growth while ADI is negative. John Neff might see a comparative advantage in operational cash viability.
45.06%
Positive 3Y OCF/share CAGR while ADI is negative. John Neff might see a big short-term edge in operational efficiency.
102.44%
Net income/share CAGR above 1.5x ADI's 65.81% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
2.85%
Positive 5Y CAGR while ADI is negative. John Neff might view this as a strong mid-term relative advantage.
248.52%
Positive short-term CAGR while ADI is negative. John Neff would see a clear advantage in near-term profit trajectory.
32.16%
10Y equity/share CAGR at 50-75% of ADI's 61.70%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
10.44%
Below 50% of ADI's 52.46%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-0.13%
Negative 3Y equity/share growth while ADI is at 18.78%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
1175.51%
10Y dividend/share CAGR above 1.5x ADI's 297.99%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
192.39%
5Y dividend/share CAGR above 1.5x ADI's 84.12%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
80.78%
3Y dividend/share CAGR above 1.5x ADI's 34.05%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
-21.34%
Firm’s AR is declining while ADI shows 3.33%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-4.52%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-1.87%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
0.58%
50-75% of ADI's 1.03%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
-0.29%
We’re deleveraging while ADI stands at 0.02%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-3.16%
Our R&D shrinks while ADI invests at 6.19%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-6.68%
We cut SG&A while ADI invests at 1.14%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.